Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.36 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 11/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154920 | 0.94 | TGFBR1 (0.35) | PPARATGFBR1TGFBR2HDAC1ACACB | |
| SCHEMBL3727835 | 0.94 | TGFBR1 (0.36) | PPARATGFBR1TGFBR2PPARGHDAC1 | |
| SCHEMBL27828792 | 0.90 | TGFBR1 (0.36) | TGFBR1TGFBR2HDAC1ACACBHDAC3 | |
| SCHEMBL3796758 | 0.88 | CYP3A4 (0.38) | PPARATGFBR1PPARGACACBCYP3A4 | |
| SCHEMBL4150410 | 0.87 | TGFBR1 (0.36) | TGFBR1TGFBR2HDAC1ACACBHDAC3 | |
| SCHEMBL4165700 | 0.86 | TGFBR1 (0.39) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL4301753 | 0.85 | TGFBR1 (0.38) | PPARATGFBR1TGFBR2PPARGCYP3A4 | |
| SCHEMBL27808346 | 0.84 | TGFBR1 (0.37) | TGFBR1TGFBR2HDAC1HDAC3HDAC2 | |
| SCHEMBL4150696 | 0.82 | TGFBR1 (0.38) | TGFBR1TGFBR2CYP3A4CYP2C8 | |
| SCHEMBL4167086 | 0.82 | CYP3A4 (0.38) | PPARATGFBR1HDAC1ACACBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| CN-101970435-A | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG | 2011-02-09 | — | — | CN | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | PPARA 765/4885TGFBR1 128/4885TGFBR2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.